A dual role of proton pump inhibition on cancer: a critical review-Reference-Cited by-同舟云学术

A dual role of proton pump inhibition on cancer: a critical review

Published:2023-02-13 Issue:2 Volume:48 Page:135-141
ISSN:1303-829X
Container-title:Turkish Journal of Biochemistry
language:en
Short-container-title:

Author:

Edizer Deniz Tuna¹²^ORCID,Akcali Zeynep¹³^ORCID,Leblebici Asım¹^ORCID,Korkut Sıla Övgü¹⁴^ORCID,Ellidokuz Ender¹⁵^ORCID

Affiliation:

1. Translational Oncology Department , Dokuz Eylul University, Oncology Institute , Izmir , Türkiye

2. Ear Nose Throat Department , Acibadem University, Acibadem Atakent Hospital , Istanbul , Türkiye

3. Nephrology Department , Ege University , Izmir , Türkiye

4. Faculty of Engineering and Architecture, Department of Engineering Sciences , Izmir Katip Celebi University , Izmir , Türkiye

5. Gastroenterolojgy Department , Dokuz Eylul University , Izmir , Türkiye

Abstract

Abstract Proton pump inhibitors (PPIs) are widely used to suppress gastric acid secretion. Proton pumps belong to the family of ATPase and among them P-ATPase and V-ATPase types regulate intracellular as well as extracellular acid equilibrium. The main aim of the current survey is to present the existing literature putting forth the relation between cancer with both the use of PPIs and proton pumps from positive and negative aspects. To perform an objective study, various types of proton pumps and their relation to cancer have been taken into account. Up to date, the studies have been considered in the time range from 2011 to 2021 via various databases (PubMed, Scopus, and Google Scholar). H+/K+ ATPase, located within the gastric parietal cells, is one of the most important examples of P-ATPases. The findings of the literature review along with criticism were presented as decreased P-ATPase expression can be used as a marker for gastric cancer diagnosis whereas the association of the proton pump with cancer may be mainly due to V-ATPase. In conclusion, molecular, epidemiological, and bioinformatic studies are required to enlighten the subject.

Publisher

Walter de Gruyter GmbH

Subject

Biochemistry (medical),Clinical Biochemistry,Molecular Biology,Biochemistry

Link

https://www.degruyter.com/document/doi/10.1515/tjb-2021-0296/pdf

Reference50 articles.

1. Amy, CE, Izumi, K, James, RG. The physiology of the gastric parietal cell. Physiol Rev 2020;100:573–602. https://doi.org/10.1152/physrev.00016.2019.

2. Huss, M, Wieczorek, H. Inhibitors of V-ATPases: old and new players. J Exp Biol 2009;212:341–6. https://doi.org/10.1242/jeb.024067.

3. Schemppvon, CM, von Schwarzenberg, K, Schreiner, S, Kubisch, R, Müller, R, Wagner, E, et al.. V-ATPase inhibition regulates anoikis resistance and metastasis of cancer cells. Mol Cancer Therapeut 2014;13:926–37. https://doi.org/10.1158/1535-7163.mct-13-0484.

4. Eaton, AF, Merkulova, M, Brown, D. The H+-ATPase (V-ATPase): from proton pump to signaling complex in health and disease. Am J Physiol Cell Physiol 2021;320:C392–414. https://doi.org/10.1152/ajpcell.00442.2020.

5. Pérez-Sayáns, M, Somoza-Martín, JM, Barros-Angueira, F, Rey, JMG, García-García, A. V-ATPase inhibitors and implication in cancer treatment. Cancer Treat Rev 2009;35:707–13. https://doi.org/10.1016/j.ctrv.2009.08.003.